Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437934 | 0.76 | ALDH1A1 (0.49) | CA12CA1CA2CA9MAPT | |
| SCHEMBL4175406 | 0.72 | PNMT (0.41) | — | |
| SCHEMBL34463424 | 0.69 | CA12 (0.36) | CA12CA1CA2CA9MAPT | |
| SCHEMBL14742904 | 0.66 | ATM (0.54) | MAPTKDM4EALDH1A1LMNAALOX15 | |
| SCHEMBL5755884 | 0.64 | ALDH1A1 (0.56) | CA12CA1CA2CA9MAPT | |
| SCHEMBL18403327 | 0.64 | CA12 (0.44) | CA12CA1CA2CA9MAPT | |
| SCHEMBL15290389 | 0.64 | MAPT (0.47) | CA12CA1CA2CA9MAPT | |
| SCHEMBL3730208 | 0.63 | ATM (0.40) | MAPTLMNAHTTATM | |
| SCHEMBL5894181 | 0.63 | ATM (0.40) | MAPTKDM4EALDH1A1LMNAGAA | |
| SCHEMBL9227699 | 0.63 | ATM (0.40) | MAPTLMNAHTTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9592243-B2 | Medical devices and methods comprising an anabolic agent for treatment of an injury | WARSAW ORTHOPEDIC, INC. (US) | 2017-03-14 | — | — | US | claimed |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | SPROUT PHARMACEUTICALS, INC. | 2008-05-01 | — | — | US | claimed |
| EP-1740181-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-10 | — | — | EP | claimed |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | claimed |
| WO-2005102342-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | VIVUS, INC. | 2004-03-04 | — | — | US | claimed |
| EP-2779996-B1 | DRUG DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF BIOACTIVE AGENTS | UPM KYMMENE CORP (FI) | 2024-04-10 | — | — | EP | disclosed |
| US-11389537-B2 | Drug delivery system for sustained delivery of bioactive agents | UPM-KYMMENE CORPORATION (FI) | 2022-07-19 | — | — | US | disclosed |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | METABASIS THERAPEUTICS INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-03-21 | — | — | US | disclosed |
| WO-2005051298-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20040248934-A1 | Tetrahydroisoquinoline derivatives as PPAR-alpha activators | PFIZER INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2004103997-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS PPAR-α ACTIVATORS | PFIZER PRODUCTS INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | PFIZER INC | 2004-10-14 | — | — | US | disclosed |
| WO-2004085401-A1 | 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | PFIZER PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | VIVUS, INC. | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | THRB, THRA, TSHR | CA12 3833/4885CA1 4352/4885CA2 4455/4885 |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | CA12 3240/4885CA1 3204/4885CA2 3631/4885 |
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | CA12 3751/4885CA1 4727/4885CA2 4077/4885 |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | TSHR, THRA, FABP1 | CA12 3223/4885CA1 3176/4885CA2 3614/4885 |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | CA12 3751/4885CA1 4727/4885CA2 4077/4885 |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | CA12 3751/4885CA1 4727/4885CA2 4077/4885 |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | LDLR, APOB, PON1 | CA12 4871/4885CA1 4833/4885CA2 4798/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | CA12 3751/4885CA1 4727/4885CA2 4077/4885 |
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | PDE12, PDE3A, PDE2A | CA12 2742/4885CA1 3443/4885CA2 877/4885 |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | CA12 3751/4885CA1 4727/4885CA2 4077/4885 |
| US-20040248934-A1 | Tetrahydroisoquinoline derivatives as PPAR-alpha activators | PPARA, PPARG, PPARD | CA12 4884/4885CA1 4876/4885CA2 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.